Lobbying disclosures · Lobbying report
ALNY: second_quarter 2026 lobbying report
Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Follow ALNY- Became public
- Jul 20, 2026, 6:06 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 3:00 PM EST
Why this is connected
Exact legal-name match: ALNYLAM PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/1178670/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/1f54558f-efb1-4839-9804-644b8fb8813a/","filing_uuid":"1f54558f-efb1-4839-9804-644b8fb8813a","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/1f54558f-efb1-4839-9804-644b8fb8813a/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-07-20T18:06:20-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 New York Avenue, NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401103321,"url":"https://lda.gov/api/v1/registrants/401103321/","house_registrant_id":null,"name":"TODD STRATEGY GROUP","description":"​Government Affairs Consulting Firm.","address_1":"1201 New York Avenue, NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-352-7761","dt_updated":"2026-07-30T17:35:40.053965-04:00"},"client":{"id":198563,"url":"https://lda.gov/api/v1/clients/198563/","client_id":176,"name":"ALNYLAM PHARMACEUTICALS, INC.","general_description":"Biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-07-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg","new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie","new":false},{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker","new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":"Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in ALNY
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Sep 9, 2026$1K–$15K
Sen. Cory A. Booker (D-NJ)
Sold (full) Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Aug 11, 2026 · disclosed Sep 9, 2026 · Spouse
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Sold Alnylam Pharmaceuticals ALNY
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Feb 15, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Jan 29, 2024 · disclosed Feb 15, 2024 · Joint
- Feb 15, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Jan 11, 2024 · disclosed Feb 15, 2024 · Joint
- Jan 7, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Alnylam Pharmaceuticals ALNY
$1K–$15K · Traded Dec 11, 2023 · disclosed Jan 7, 2024 · Joint
- Apr 17, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Bought Alnylam Pharmaceuticals ALNY
$15K–$50K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
- Feb 24, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Sold Alnylam Pharmaceuticals ALNY
$15K–$50K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.